Pharma Mar, S.A. (FRA:PMRA)

Market Cap	1.45B +1.1%
Revenue (ttm)	218.64M +15.5%
Net Income	56.13M +33.6%
EPS	3.11 +29.1%
Shares Out	n/a
PE Ratio	25.90
Forward PE	17.73
Dividend	1.00 (1.21%)
Ex-Dividend Date	Jul 8, 2026

Volume	n/a
Open	83.80
Previous Close	82.40
Day's Range	83.80 - 83.80
52-Week Range	65.50 - 105.60
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 30, 2026

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer; Zepzelca, a synthetic compound designed to...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1986
• Employees: 505
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PMRA

Financial Performance

In 2025, Pharma Mar's revenue was 221.39 million, an increase of 26.61% compared to the previous year's 174.86 million. Earnings were 74.99 million, an increase of 187.03%.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error